UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will particip ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...

Sanofi, GlaxoSmithKline, Abbott Biologicals, Bilthoven Biologicals, and Bharat Biotech International Lead the Global CompetitionDublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "BCG Vaccine Global Market ...

The management of intravesical and urethral foreign bodies (FBs) is a complex area of urology that presents unique challenges, particularly in pediatric populations. Foreign bodies in the urinary ...

J&J is developing a second Taris-derived candidate called TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), and has predicted that peak sales of the two ...

Imagine a career in a field you can’t imagine. Dominique Constantini parlayed her commitment to immunology to meeting unmet clinical needs and building a potentially billion-dollar business along the ...

TAR-200 is an intravesical drug releasing system that provides sustained local delivery of the chemotherapy drug gemcitabine into the bladder. The system is inserted into the bladder using a co ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

UroGen Pharma (URGN) announced that the three-month complete response rate and 12-month durability of response from the Phase 3 ENVISION study ...